NORTH BRUNSWICK, N.J., September 2, 2008 –- WellGen, Inc. today announced that Robert J. Bertoldi has been appointed interim Chief Executive Officer.
Mr. Bertoldi will assume the position of CEO in addition to his role as President and Chief Financial Officer of Amphion Innovations plc (LSE: AMP). Amphion, a developer of medical and technology businesses, is a significant shareholder in WellGen. He succeeds Dr. Kathleen P. Mullinix.
Mr. Bertoldi stated, “I am pleased to take on this responsibility and want to thank Dr. Mullinix for her service over the past two years.”
Mr. Bertoldi was a founder, President, and CFO of Amphion Capital Partners LLC (Amphion Innovations’ predecessor company) and VennWorks LLC. Mr. Bertoldi is also a general partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP). Prior to that, he served as Chief Financial Officer for James D. Wolfensohn, Inc. and Hambro America Inc. He began his career at KPMG and left as a manager in the investment services department. Mr. Bertoldi received a B.A. in Accounting and Economics from Queens College, New York in 1976 and became a Certified Public Accountant in 1978. He is a member of the AICPA and NYSCPA.
03/03/10
Study Results Revealed
01/08/10
“About Harvest” Podcast Features WellGen
12/07/09
WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities
11/18/09
WellGen Recognized as Nutraceutical “Innovator” by Global Business Insights
04/07/09
Dr. Roddy Carter Named President and Chief Executive Officer
09/02/08
Robert J. Bertoldi Appointed Interim Chief Executive Officer of WellGen
02/12/08
WellGen Names Robert M. Hellauer as Chief Financial Officer
12/18/07
WellGen Names Nancy E. Rawson, Ph.D., Chief Scientific Officer
08/24/10
Health Benefits from Tea: Perception vs. Reality
06/01/10
The Scientific & Medical Significance of Inflammation
03/17/10
Modulating Inflammation Provides Clinical Benefits for Diabetes
03/03/10
Study Results Revealed
10/01/09
Diabetes Connections
12/18/07
WellGen Names Nancy E. Rawson, Ph.D., Chief Scientific Officer